This funding opportunity supports advanced pre-clinical research focused on translating nanotechnology-based cancer diagnostics and therapeutics. It targets development of experimental nanomedicines using nanoparticles and nano-devices designed to enhance cancer treatment effectiveness. The award aims to mature these interventions toward clinical translational programs such as NCI Experimental Therapeutics (NExT). Clinical trials are not allowed under this award.
Eligible applicants include a wide range of U.S. organizations such as state and local governments, nonprofits, institutions of higher education, small businesses, tribal governments, and others. Non-U.S. entities are not eligible to apply, but foreign components of U.S. organizations are allowed.
